Damora Therapeutics, Inc. (DMRA) insider trading
Damora Therapeutics, Inc. insiders have made 1 open-market purchase worth $253k since Sep 28, 2026, by 1 insider. The latest: Jennifer Jarrett (President) bought $253k, filed Sep 28, 2026, scored 47 out of 100.
Follow DMRA, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Insider purchases
| Filed | Insider | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Sep 28 Form 4 (opens sec.gov) |
Jennifer JarrettPresidentPresident | +3% stake | 47 | $253k 12,500 at $20.23 |
−2.6% | +4.1% |
Track record (hypothetical): a week after the filing, these buys averaged −2.6% (0% up, 1 measured); a month after, +4.1% (100% up, 1 measured).
Insiders who bought DMRA
- Jennifer Jarrett President
Questions
Are insiders buying DMRA stock?
Yes. In the last 90 days, 1 open-market purchase was filed, worth $253k.
Who bought DMRA stock most recently?
Jennifer Jarrett, President, bought 12,500 shares for $253k (Form 4 (opens sec.gov), filed Sep 28, 2026).
How does InsiderBeacon score an insider buy?
Out of 100, from who bought, how much their stake grew, the size of the trade, whether other insiders bought within ten days, where the price sat in its 52-week range, and whether it was a first or a routine buy. The score is fixed when the filing arrives. The formula and the research behind it.
Insiders are also buying, same industry
Data as of Sep 28, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer